Valneva’s (VALN) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Valneva (NASDAQ:VALN) in a research note issued to investors on Monday,Benzinga reports. They currently have a $17.00 price objective on the stock.

Separately, Guggenheim lowered their price target on shares of Valneva from $17.00 to $15.00 and set a “buy” rating for the company in a report on Monday, March 24th.

Valneva Trading Down 7.6 %

VALN stock opened at $6.71 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The stock has a market capitalization of $545.26 million, a price-to-earnings ratio of -51.62 and a beta of 1.93. The business has a fifty day moving average price of $6.67 and a 200 day moving average price of $5.59. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $9.50.

Valneva (NASDAQ:VALN) last announced its earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The business had revenue of $56.48 million during the quarter, compared to analyst estimates of $55.64 million. Analysts expect that Valneva will post 0.13 EPS for the current fiscal year.

Institutional Trading of Valneva

A hedge fund recently raised its stake in Valneva stock. Wells Fargo & Company MN boosted its stake in Valneva SE (NASDAQ:VALN) by 14.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 246,766 shares of the company’s stock after purchasing an additional 30,859 shares during the quarter. Wells Fargo & Company MN owned about 0.30% of Valneva worth $1,079,000 as of its most recent SEC filing. 11.39% of the stock is owned by hedge funds and other institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.